Arena Pharmaceuticals (ARNA) Hits New 1-Year High at $43.32
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reached a new 52-week high on Friday . The company traded as high as $43.32 and last traded at $43.40, with a volume of 518202 shares. The stock had previously closed at $40.67.
A number of analysts have recently weighed in on the stock. Leerink Swann reiterated a “positive” rating and set a $56.00 target price (up from $53.00) on shares of Arena Pharmaceuticals in a report on Wednesday, January 17th. BidaskClub lowered shares of Arena Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 19th. Wells Fargo & Co upgraded shares of Arena Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Wednesday, January 3rd. ValuEngine upgraded shares of Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Finally, Zacks Investment Research lowered shares of Arena Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $45.13.
The company has a market capitalization of $1,702.84, a price-to-earnings ratio of -46.63 and a beta of 1.51. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.42 and a quick ratio of 4.32.
TRADEMARK VIOLATION WARNING: “Arena Pharmaceuticals (ARNA) Hits New 1-Year High at $43.32” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/03/04/arena-pharmaceuticals-arna-hits-new-1-year-high-at-43-32.html.
About Arena Pharmaceuticals
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.